Johnson & Johnson's immunology, cancer blockbusters deliver Q3 growth—and fuel hopes for 2021

Johnson & Johnson managed to beat the market on pharma growth in the third quarter—and with new launches still on their way and newer meds pumping out sales, the company feels even better about 2021.

Seven of the company’s branded pharmaceuticals—Erleada, Darzalex, Imbruvica, Stelara, Tremfya, Opsumit and Uptravi—grew at double-digit percentages in Q3. Stelara and Tremfya led the immunology portfolio, which altogether pulled in $3.8 billion and ranked as the company's largest franchise. Stelara itself generated nearly $2 billion during the quarter.